TEMPLATE

Leaders in Learning: Publications of Faculty & Staff

Oncology 2002-2003

BATTISTA, J.

Lindsay, P., V. Moiseenko, J. Van Dyk, and J. Battista. 2003. The influence of brachytherapy dose heterogeneity on estimates of alpha/beta for prostate cancer. Physics in Medicine and Biology 48 (4): 507-522.

Lindsay, PE., J. Van Dyk, and J.J. Battista. 2003. A systematic study of imaging uncertainties and their impact on 125I prostate brachytherapy dose evaluation. Medical Physics 30 (7): 1897-1908.

BAUMAN G

Brundage, M., H. Lukka, J. Crook, P. Warde, G. Bauman, C. Catton, B. Markman, and M. Charette. 2002. The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 low or intermediate risk prostate cancer - a systematic review. Radiotherapy and Oncology 64 (3): 239-250.

BERG, R

Kanwar, J., R. Berg, Y. Yang, R. Kanwar, L. Ching, X. Sun, and G. Krissansen. 2003. Requirements for ICAM-1 immunogene therapy of lymphoma. Cancer Gene Therapy 10 (6): 468-476.

CAIRNCROSS, G.

Laperriere, N., L. Zuraw, G. Cairncross, and Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group. 2002. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiotherapy and Oncology 64 (3): 259-273.

Watling, C., and G. Cairncross. 2002. Acetazolamide therapy for symptomatic plateau waves in patients with brain tumors. Report of three cases. Journal of Neurosurgery 97 (1): 224-226.

CHAMBERS, A.F.

Chambers, A.F., and A.B. Tuck. 2002. Osteopontin: A ras-regulated gene that contributed to tumor metastasis. Cancer Metastasis-Related Genes. 3rd ed. D.R. Welch. Dordrecht: Kluwer Academic Publishers. 13: 231-236.

Chambers, A.F., and H. Varghese. 2002. Oncogenes as a therapeutic target to prevent metastasis. Oncogene-Directed Therapies. J.W. Rak. Totowa, NJ: The Humana Press Inc. 11: 219-228.

Denhardt, D.T., D. Mistretta, A.F. Chambers, S. Krishna, J.F. Porter, S. Raghuran, and S.R. Rittling. 2002. Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter. Clinical & Experimental Metastasis 20 (1): 77-84.

Hotte, S.J., E.W. Winquist, L. Sitt, S.M. Wilson, and A.F. Chambers. 2002. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 95 (3): 506-512.

MacDonald, I.C., A.C. Groom, and A.F. Chambers. 2002. Cancer spread and micrometastasis development: quantitative approaches for in vivo models. Bioessays 24 (10): 885-893.

Tuck, A.B., C. Hota, S. Wilson, and A.F. Chambers. 2003. Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene 22 (8): 1198-1205.

Welch, D.R., and A.F. Chambers (Editors). 2002. Clinical & Experimental Metastasis (Special Issues: Genes and Metastasis). 20 (1,2). 1-90, 91-185 pp.

CHEN, J.

Grigorov, G., T. Kron, E. Wong, J. Chen, J. Sollazzo, and G. Rodrigues. 2003. Optimization of helical tomotherapy treatment plans for prostate cancer. Physics in Medicine & Biology 48 (13): 1933-1944.

DAR, A.R.

Keith, B., M. Vincent, L. Stitt, A. Tomiak, R. Malthaner, E. Yu, P. Truong, R. Inculet, M. Lefcoe, A.R. Dar, W. Kocha, and I. Craig. 2002. Subsets more likely to benefit from surgery or prophylactic cranial irradiation after chemoradiation for localized non-small-cell lung cancer. American Journal of Clinical Oncology 25 (6): 583-587.

Videtic, G.M., L.W. Stitt, A.R. Dar, W.I. Kocha, A.T. Tomiak, P.T. Truong, M.D. Vincent, and E.W. Yu. 2003. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. Journal of Clinical Oncology 21 (8): 1544-1549.

DIMATTIA, G.E.

Paciga, M., A.J. Watson, G.E. DiMattia, and G.F. Wagner. 2002. Ovarian stanniocalcin is structurally unique in mammals and its production and release are regulated through the luteinizing hormone receptor. Endocrinology 143 (10): 3925-3934.

HAMMOND, J.A.

Groome, P.A., B. O'Sullivan, J.C. Irish, D.M. Rothwell, K. Schulze, P.R. Warde, K.M. Schneider, R.G. Mackenzie, D.I. Hodson, J.A. Hammond, S.P. Gulavita, L.J. Eapen, P.F. Dixon, R.J. Bissett, and W.J. Mackillop. 2003. Management and outcome differences in supraglottic cancer between Ontario, Canada and the Surveillance, Epidemiology, and End Results areas of the United States. Journal of Clinical Oncology 21 (3): 496-505.

KOCHA, W.

KOROPATNICK, J.

Berg, R., P. Ferguson, J. DeMoor, M. Vincent, and J. Koropatnick. 2002. The means to an end of tumor cell resistance to chemotherapeutic drugs targeting thymidylate synthase: shoot the messenger. Current Drug Targets 3 (4): 297-309.

Berg, R., P. Ferguson, M. Vincent, and J. Koropatnick. 2003. A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance. Cancer Gene Therapy 10 (4): 278-286.

Gabril, M., T. Onita, P. Ji, H. Sakai, F. Chan, J. Koropatnick, J. Chin, M. Moussa, and J. Xuan. 2002. Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model. Gene Therapy 9 (23): 1589-1599.

KRON, T.

Kron, T., K. Barnes, and P. O'Brien. 2003. Multicentre dosimetric comparison of photon-junctioning techniques in head and neck radiotherapy. Australasian Radiology 47 (3): 289-294.

MACDONALD, D.R.

Mason, W.P., F. Gentili, D.R. Macdonald, S. Hariharan, C.R. Cruz, and L.E. Abrey. 2002. Stablization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. Journal of Neurosurgery 97 (2): 341-346.

MOULIN, D.

Moulin, D., A. Clark, M. Speechley, and P. Morley-Forster. 2002. Chronic pain in Canada - prevalence, treatment, impact and the role of opioid analgesia. Pain Research & Management Winter 7 (4): 179-184.

MYMRYK, J.

Avvakumov, N., J. Torchia, and J. Mymryk. 2003. Interaction of the HPV E7 proteins with the pCAF acetyltransferase. Oncogene 22 (25): 3833-3841.

Avvakumov, N., R. Wheeler, J. D'Halluin, and J. Mymryk. 2002. Comparative sequence analysis of the largest E1A proteins of human and simian adenoviruses. Journal of Virology 76 (16): 7968-7975.

Meng, X., Y. Yang, X. Cao, M. Govindan, M. Shuen, A. Hollenberg, J. Mymryk, and P. Walfish. 2003. Cellular context of coregulator and adaptor proteins regulates human adenovirus 5 early region 1A-dependent gene activation by the thyroid hormone receptor. Molecular Endocrinology 17 (6): 1095-1105.

Shuen, M., N. Avvakumov, P. Walfish, C. Brandl, and J. Mymryk. 2002. The adenovirus E1A protein targets the SAGA but not the ADA transcriptional regulatory complex through multiple independent domains. The Journal of Biological Chemistry 277 (34): 30844-30851.

RODRIGUES, G.

TORCHIA, J.

Avvakumov, N., J. Torchia, and J. Mymryk. 2003. Interaction of the HPV E7 proteins with the pCAF acetyltransferase. Oncogene 22 (25): 3833-3841.

Dellaire, G., E. Makarov, J. Cowger, D. Longman, H. Sutherland, R. Luhrmann, J. Torchia, and W. Bickmore. 2002. Mammalian PRP4 kinase copurifies and interacts with components of both the U5 snRNP and the N-CoR deacetylase complexes. Molecular and Cellular Biology 22 (14): 5141-5156.

Qutob, M., R. Bhattacharjee, E. Pollari, S. Yee, and J. Torchia. 2002. Microtubule-dependent subcellular redistribution of the transcriptional coactivator p/CIP. Molecular and Cellular Biology 22 (18): 6611-6626.

Weston, A., R. Chandraratna, J. Torchia, and T. Underhill. 2002. Requirement for RAR-mediated gene repression in skeletal progenitor differentiation. The Journal of Cell Biology 158 (1): 39-51.

TURLEY, E.

Hall, C., F. Wang, and E. Turley. 2002. Src-/- fibroblasts are defective in their ability to disassemble focal adhesions in response to phorbol ester/hyaluronan treatment. Cell Communication & Adhesion 9 (5-6): 273-283.

O'Connor, J., M. Bonham, E. Turley, A. McKeown, V. McKelvey-Martin, W. Gilmore, and J. Strain. 2003. Copper supplementation has no effect on markers of DNA damage and liver function in healthy adults (FOODCUE Project). Annals of Nutrition & Metabolism 47 (5): 201-206.

Wang, F., R. Hansen, D. Radisky, T. Yoneda, M. Barcellos-Hoff, O. Petersen, E. Turley, and M. Bissell. 2002. Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. Journal of the National Cancer Institute 94 (19): 1494-1503.

VAN DYK, J.

Khan, M., J. Van Dyk, I. Yeung, and R. Hill. 2003. Partial volume rat lung irradiation; assessment of early DNA damage in different lung regions and effect of radical scavengers. Radiotherapy and Oncology 66 (1): 95-102.

Moiseenko, V., T. Craig, A. Bezjak, and J. Van Dyk. 2003. Dose-volume analysis of lung complications in the radiation treatment of malignant thymoma: a retrospective review. Radiotherapy and Oncology 67 (3): 265-274.

Reft, C., R. Alecu, I.J. Das, B.J. Gerbi, P. Keall, E. Lief, B.J. Mijnheer, N. Papanikolaou, C. Sibata, J. Van Dyk, and AAPM Radiation Therapy Committee Task Group 63. 2003. Dosimetric considerations for patients with HIP prostheses undergoing pelvic irradiation. Report of the AAPM Radiation Therapy Committee Task Group 63. Medical Physics 30 (6): 1162-1182.

VANDENBERG, T.A.

Gelmon, KA., TA. Vandenberg, L. Panasci, B. Norris, M. Crump, L. Douglas, W. Walsh, SJ. Matthews, and LK. Seymour. 2003. A phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group trial, IND 129. Annals of Oncology 14 (4): 543-548.

VENKATESAN, V.M.

Fung, K., V.M. Venkatesan, J.G. Heathcote, H.B. Lampe, and M. Edmonds. 2002. Tumefactive fibroinflammatory lesions of the head and neck: role of corticosteroids, radiotherapy and surgery. The Journal of Otolaryngology 31 (4): 253-256.

VINCENT, M.

Douillard, J., P. Hoff, J. Skillings, P. Eisenberg, N. Davidson, P. Harper, M. Vincent, B. Lembersky, S. Thompson, A. Maniero, and S. Benner. 2002. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. Journal of Clinical Oncology 20 (17): 3605-3616.

Vincent, M., C. Ho, A. Tomiak, E. Winquist, F. Whiston, and L. Stitt. 2002. Toxicity analysis of the 5-day bolus 5-fluorouracil/folinic acid regimen for the treatment of colorectal carcinoma from 2 randomized controlled trials: A concern about dose. Clinical Colorectal Cancer 2 (2): 111-118.

WINQUIST, E.

Bella, A., E. Winquist, and E. Perlman. 2002. Primary synovial sarcoma of the kidney diagnosed by molecular detection of SYT-SSC fusion transcripts. The Journal of Urology 168 (3): 1092-1093.

Segal, R., E. Winquist, H. Lukka, J. Chin, M. Brundage, and B. Markman. 2002. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline. The Canadian Journal of Urology 9 (5): 1625-1633.

WONG, E.

YEE, S.

Feng, Q., W. Song, X. Lu, J. Hamilton, M. Lei, T. Peng, and S. Yee. 2002. Development of heart failure and congenital septal defects in mice lacking endothelial nitric oxide synthase. Circulation 106 (7): 873-879.

YOUNUS, J.

Younus, J., I. Simpson, A. Collins, and X. Wang. 2003. Mind Control of Menopause. Women's Health Issues 13 (2): 74-78.

YU, E.